Leap Therapeutics Inc (LPTX) - Total Assets
Based on the latest financial reports, Leap Therapeutics Inc (LPTX) holds total assets worth $11.40 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Leap Therapeutics Inc to assess how comfortably operating cash covers total debt obligations.
Leap Therapeutics Inc - Total Assets Trend (2012–2024)
This chart illustrates how Leap Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Leap Therapeutics Inc (LPTX) net assets for net asset value and shareholders' equity analysis.
Leap Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Leap Therapeutics Inc's total assets of $11.40 Million consist of 97.8% current assets and 2.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 96.2% |
| Accounts Receivable | $704.00K | 1.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Leap Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Leap Therapeutics Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Leap Therapeutics Inc's current assets represent 97.8% of total assets in 2024, an increase from 90.4% in 2012.
- Cash Position: Cash and equivalents constituted 96.2% of total assets in 2024, up from 86.5% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 7.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 1.4% of total assets.
Leap Therapeutics Inc Competitors by Total Assets
Key competitors of Leap Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Leap Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.21 | 3.97 | 7.09 |
| Quick Ratio | 1.21 | 3.97 | 7.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.79 Million | $47.72 Million | $44.90 Million |
Leap Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Leap Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 27.25 |
| Latest Market Cap to Assets Ratio | 2.36 |
| Asset Growth Rate (YoY) | -32.5% |
| Total Assets | $49.12 Million |
| Market Capitalization | $116.14 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Leap Therapeutics Inc's assets at a significant premium (2.36x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Leap Therapeutics Inc's assets decreased by 32.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Leap Therapeutics Inc (2012–2024)
The table below shows the annual total assets of Leap Therapeutics Inc from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $49.12 Million | -32.55% |
| 2023-12-31 | $72.83 Million | +25.36% |
| 2022-12-31 | $58.09 Million | -50.73% |
| 2021-12-31 | $117.91 Million | +67.45% |
| 2020-12-31 | $70.42 Million | +845.44% |
| 2019-12-31 | $7.45 Million | -60.95% |
| 2018-12-31 | $19.07 Million | -34.37% |
| 2017-12-31 | $29.06 Million | +350.09% |
| 2016-12-31 | $6.46 Million | -77.06% |
| 2015-12-31 | $28.15 Million | -42.20% |
| 2014-12-31 | $48.70 Million | +134.83% |
| 2013-12-31 | $20.74 Million | +17.10% |
| 2012-12-31 | $17.71 Million | -- |
About Leap Therapeutics Inc
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-… Read more